Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 283

1.

The Buoyancy of Cryptococcus neoformans Is Affected by Capsule Size.

Vij R, Cordero RJB, Casadevall A.

mSphere. 2018 Nov 7;3(6). pii: e00534-18. doi: 10.1128/mSphere.00534-18.

2.

Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales.

Tay J, Vij R, Norkin M, Buadi F, Kindwall-Keller TL, Roberts JS, White DJ, Wood RP, Blanthorn-Hazell SE, Rossi AC, Dhanasiri S, Zafar F, Newhouse K, McCurdy AR.

Leuk Lymphoma. 2018 Oct 31:1-8. doi: 10.1080/10428194.2018.1523399. [Epub ahead of print]

PMID:
30380358
3.

Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3.

Slaga D, Ellerman D, Lombana TN, Vij R, Li J, Hristopoulos M, Clark R, Johnston J, Shelton A, Mai E, Gadkar K, Lo AA, Koerber JT, Totpal K, Prell R, Lee G, Spiess C, Junttila TT.

Sci Transl Med. 2018 Oct 17;10(463). pii: eaat5775. doi: 10.1126/scitranslmed.aat5775.

PMID:
30333240
4.

The Escherichia coli β-barrel assembly machinery is sensitized to perturbations under high membrane fluidity.

Storek KM, Vij R, Sun D, Smith PA, Koerber JT, Rutherford ST.

J Bacteriol. 2018 Oct 15. pii: JB.00517-18. doi: 10.1128/JB.00517-18. [Epub ahead of print]

5.

Evaluation of anti-diabetic attributes of Lactobacillus rhamnosus MTCC: 5957, Lactobacillus rhamnosus MTCC: 5897 and Lactobacillus fermentum MTCC: 5898 in streptozotocin induced diabetic rats.

Yadav R, Dey DK, Vij R, Meena S, Kapila R, Kapila S.

Microb Pathog. 2018 Dec;125:454-462. doi: 10.1016/j.micpath.2018.10.015. Epub 2018 Oct 11.

PMID:
30316007
6.

Bones in Multiple Myeloma: Imaging and Therapy.

Zamagni E, Cavo M, Fakhri B, Vij R, Roodman D.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):638-646. doi: 10.1200/EDBK_205583. Review.

7.

Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment: An Observational Cohort Study with Independent Validation.

Adegunsoye A, Oldham JM, Bonham C, Hrusch C, Nolan P, Klejch W, Bellam S, Mehta U, Thakrar K, Pugashetti JV, Husain AN, Montner SM, Straus CM, Vij R, Sperling AI, Noth I, Strek ME, Chung JH.

Am J Respir Crit Care Med. 2018 Sep 14. doi: 10.1164/rccm.201804-0761OC. [Epub ahead of print]

PMID:
30216085
8.

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.

Cella D, McKendrick J, Kudlac A, Palumbo A, Oukessou A, Vij R, Zyczynski T, Davis C.

Ann Hematol. 2018 Dec;97(12):2455-2463. doi: 10.1007/s00277-018-3469-4. Epub 2018 Sep 4.

9.

Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.

Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK.

Biol Blood Marrow Transplant. 2018 Aug 25. pii: S1083-8791(18)30489-0. doi: 10.1016/j.bbmt.2018.08.018. [Epub ahead of print]

PMID:
30153491
10.

Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.

Jurczyszyn A, Davila J, Kortüm KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wiśniewska-Piąty K, Waszczuk-Gajda A, Crusoe E, Hajek R, Robak P, Raźny M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH.

Leuk Lymphoma. 2018 Jul 22:1-6. doi: 10.1080/10428194.2018.1480766. [Epub ahead of print]

PMID:
30033832
11.

Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment.

Malecek MK, Fiala M, Schroeder M, Dukeman J, Ghobadi A, Stockerl-Goldstein K, Wildes T, Vij R.

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):e363-e364. doi: 10.1016/j.clml.2018.06.008. Epub 2018 Jun 21. No abstract available.

PMID:
30001984
12.

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.

Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząśko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH.

Leuk Lymphoma. 2018 Jul 2:1-6. doi: 10.1080/10428194.2018.1473574. [Epub ahead of print]

PMID:
29965787
13.

An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.

Zheng B, Yu SF, Del Rosario G, Leong SR, Lee GY, Vij R, Chiu CPC, Liang WC, Wu Y, Chalouni C, Sadowsky J, Clark VM, Hendricks A, Poon KA, Chu YW, Pillow TH, Schutten MM, Flygare JA, Polson AG.

Clin Cancer Res. 2018 Jun 29. pii: clincanres.0333.2018. doi: 10.1158/1078-0432.CCR-18-0333. [Epub ahead of print]

PMID:
29959143
14.

Analysis of the effect of promoter type and skin pretreatment on antigen expression and antibody response after gene gun-based immunization.

Vij R, Lin Z, Schneider K, Seshasayee D, Koerber JT.

PLoS One. 2018 Jun 1;13(6):e0197962. doi: 10.1371/journal.pone.0197962. eCollection 2018.

15.

The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant.

Manjappa S, Fiala MA, King J, Kohnen DA, Vij R.

Bone Marrow Transplant. 2018 May 24. doi: 10.1038/s41409-018-0216-3. [Epub ahead of print] No abstract available.

PMID:
29795420
16.

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma.

Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A.

Leuk Lymphoma. 2018 May 9:1-9. doi: 10.1080/10428194.2018.1459609. [Epub ahead of print]

PMID:
29741423
17.

A targeted boost-and-sort immunization strategy using Escherichia coli BamA identifies rare growth inhibitory antibodies.

Vij R, Lin Z, Chiang N, Vernes JM, Storek KM, Park S, Chan J, Meng YG, Comps-Agrar L, Luan P, Lee S, Schneider K, Bevers J 3rd, Zilberleyb I, Tam C, Koth CM, Xu M, Gill A, Auerbach MR, Smith PA, Rutherford ST, Nakamura G, Seshasayee D, Payandeh J, Koerber JT.

Sci Rep. 2018 May 8;8(1):7136. doi: 10.1038/s41598-018-25609-z.

18.

African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis.

Adegunsoye A, Oldham JM, Bellam SK, Chung JH, Chung PA, Biblowitz KM, Montner S, Lee C, Hsu S, Husain AN, Vij R, Mutlu G, Noth I, Churpek MM, Strek ME.

Eur Respir J. 2018 Jun 14;51(6). pii: 1800255. doi: 10.1183/13993003.00255-2018. Print 2018 Jun.

19.

Differentiating Usual Interstitial Pneumonia From Nonspecific Interstitial Pneumonia Using High-resolution Computed Tomography: The "Straight-edge Sign".

Zhan X, Koelsch T, Montner SM, Zhu A, Vij R, Swigris JJ, Chung JH.

J Thorac Imaging. 2018 Jul;33(4):266-270. doi: 10.1097/RTI.0000000000000328.

PMID:
29683868
20.

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.

Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M.

Cancer. 2018 Jun 15;124(12):2541-2551. doi: 10.1002/cncr.31374. Epub 2018 Apr 12.

PMID:
29645093
21.

Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.

Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ; Fusion Analysis Working Group; Cancer Genome Atlas Research Network, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L.

Cell Rep. 2018 Apr 3;23(1):227-238.e3. doi: 10.1016/j.celrep.2018.03.050.

22.

Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow.

Bansal D, Vij K, Chang GS, Miller CA, DiPersio JF, Vij R, Heath SE, Westervelt P, Welch JS, Fehniger TA.

Haematologica. 2018 Jun;103(6):e270-e273. doi: 10.3324/haematol.2017.184168. Epub 2018 Mar 22. No abstract available.

23.

A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.

White BS, Lanc I, O'Neal J, Gupta H, Fulton RS, Schmidt H, Fronick C, Belter EA Jr, Fiala M, King J, Ahmann GJ, DeRome M, Mardis ER, Vij R, DiPersio JF, Levy J, Auclair D, Tomasson MH.

Blood Cancer J. 2018 Mar 21;8(3):35. doi: 10.1038/s41408-018-0062-y.

24.

Monoclonal antibody targeting the β-barrel assembly machine of Escherichia coli is bactericidal.

Storek KM, Auerbach MR, Shi H, Garcia NK, Sun D, Nickerson NN, Vij R, Lin Z, Chiang N, Schneider K, Wecksler AT, Skippington E, Nakamura G, Seshasayee D, Koerber JT, Payandeh J, Smith PA, Rutherford ST.

Proc Natl Acad Sci U S A. 2018 Apr 3;115(14):3692-3697. doi: 10.1073/pnas.1800043115. Epub 2018 Mar 19.

25.

CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines.

Chung JH, Oldham JM, Montner SM, Vij R, Adegunsoye A, Husain AN, Noth I, Lynch DA, Strek ME.

AJR Am J Roentgenol. 2018 May;210(5):1034-1041. doi: 10.2214/AJR.17.18947. Epub 2018 Mar 16.

PMID:
29547052
26.

The capsule of Cryptococcus neoformans.

Casadevall A, Coelho C, Cordero RJB, Dragotakes Q, Jung E, Vij R, Wear MP.

Virulence. 2018 Aug 1:1-10. doi: 10.1080/21505594.2018.1431087. [Epub ahead of print]

PMID:
29436899
27.

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.

Richardson PG, Bensinger WI, Huff CA, Costello CL, Lendvai N, Berdeja JG, Anderson LD Jr, Siegel DS, Lebovic D, Jagannath S, Laubach JP, Stockerl-Goldstein KE, Kwei L, Clow F, Elias L, Salman Z, Graef T, Bilotti E, Vij R.

Br J Haematol. 2018 Mar;180(6):821-830. doi: 10.1111/bjh.15058. Epub 2018 Feb 13.

28.

N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia.

Oldham JM, Witt LJ, Adegunsoye A, Chung JH, Lee C, Hsu S, Chen LW, Husain A, Montner S, Vij R, Strek ME, Noth I.

BMC Pulm Med. 2018 Feb 8;18(1):30. doi: 10.1186/s12890-018-0599-3.

29.

Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.

Wong TN, Miller CA, Jotte MRM, Bagegni N, Baty JD, Schmidt AP, Cashen AF, Duncavage EJ, Helton NM, Fiala M, Fulton RS, Heath SE, Janke M, Luber K, Westervelt P, Vij R, DiPersio JF, Welch JS, Graubert TA, Walter MJ, Ley TJ, Link DC.

Nat Commun. 2018 Jan 31;9(1):455. doi: 10.1038/s41467-018-02858-0.

30.

Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation.

Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR.

Bone Marrow Transplant. 2018 Jul;53(7):932-937. doi: 10.1038/s41409-018-0100-1. Epub 2018 Jan 30. No abstract available.

31.

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK.

J Clin Oncol. 2018 Mar 20;36(9):859-866. doi: 10.1200/JCO.2017.75.5207. Epub 2018 Jan 30.

PMID:
29381435
32.

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.

Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A.

Leukemia. 2018 Apr;32(4):986-995. doi: 10.1038/leu.2017.331. Epub 2017 Nov 16.

33.

Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.

de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, Alhallak K, Shah S, Muz B, Sun J, King J, Kohnen D, Salama NN, Achilefu S, Vij R, Azab AK.

J Control Release. 2018 Jan 28;270:158-176. doi: 10.1016/j.jconrel.2017.11.045. Epub 2017 Nov 28.

PMID:
29196043
34.

CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Disease-Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis.

Chung JH, Cox CW, Montner SM, Adegunsoye A, Oldham JM, Husain AN, Vij R, Noth I, Lynch DA, Strek ME.

AJR Am J Roentgenol. 2018 Feb;210(2):307-313. doi: 10.2214/AJR.17.18384. Epub 2017 Nov 15.

PMID:
29140119
35.

Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.

Komrokji R, Swern AS, Grinblatt D, Lyons RM, Tobiasson M, Silverman LR, Sayar H, Vij R, Fliss A, Tu N, Sugrue MM.

Oncologist. 2018 Feb;23(2):159-170. doi: 10.1634/theoncologist.2017-0215. Epub 2017 Nov 8.

PMID:
29118268
36.

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.

Medeiros BC, McCaul K, Kambhampati S, Pollyea DA, Kumar R, Silverman LR, Kew A, Saini L, Beach CL, Vij R, Wang X, Zhong J, Gale RP.

Haematologica. 2018 Jan;103(1):101-106. doi: 10.3324/haematol.2017.172353. Epub 2017 Nov 2.

37.

Autoimmune Hypothyroidism As a Predictor of Mortality in Chronic Hypersensitivity Pneumonitis.

Adegunsoye A, Oldham JM, Husain AN, Chen L, Hsu S, Montner S, Chung JH, Vij R, Noth I, Strek ME.

Front Med (Lausanne). 2017 Oct 16;4:170. doi: 10.3389/fmed.2017.00170. eCollection 2017.

38.

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.

Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS.

Cancer Med. 2017 Dec;6(12):2814-2821. doi: 10.1002/cam4.1231. Epub 2017 Oct 23.

39.

Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma.

Ghai A, Maji D, Cho N, Chanswangphuwana C, Rettig M, Shen D, DiPersio J, Akers W, Dehdashti F, Achilefu S, Vij R, Shokeen M.

J Nucl Med. 2018 Feb;59(2):216-222. doi: 10.2967/jnumed.117.196063. Epub 2017 Oct 12.

40.

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C.

Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.

PMID:
29018077
41.

CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.

Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Becker-Hapak M, Schappe T, Abdel-Latif S, Ireland AR, Jaishankar D, King JA, Vij R, Clement D, Goodridge J, Malmberg KJ, Wong HC, Fehniger TA.

J Clin Invest. 2017 Nov 1;127(11):4042-4058. doi: 10.1172/JCI90387. Epub 2017 Oct 3.

42.

Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort.

Adegunsoye A, Oldham JM, Chung JH, Montner SM, Lee C, Witt LJ, Stahlbaum D, Bermea RS, Chen LW, Hsu S, Husain AN, Noth I, Vij R, Strek ME, Churpek M.

Chest. 2018 Feb;153(2):349-360. doi: 10.1016/j.chest.2017.09.026. Epub 2017 Sep 28.

PMID:
28964798
43.

Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort.

Sharma N, Putman MS, Vij R, Strek ME, Dua A.

J Rheumatol. 2017 Nov;44(11):1612-1618. doi: 10.3899/jrheum.161217. Epub 2017 Sep 1.

PMID:
28864644
44.

Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.

Lee YS, Liu J, Fricano KA, Webb EM, Toolsie DR, Jones S, Rhoads JA, Vij R, Cashen AF, Abboud CN, Westervelt P, Bartlett NL, Dipersio JF, Kreisel FH, Lim KH.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2199-2204. doi: 10.1016/j.bbmt.2017.08.022. Epub 2017 Aug 26.

PMID:
28847710
45.

Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis.

Adegunsoye A, Oldham JM, Fernández Pérez ER, Hamblin M, Patel N, Tener M, Bhanot D, Robinson L, Bullick S, Chen L, Hsu S, Churpek M, Hedeker D, Montner S, Chung JH, Husain AN, Noth I, Strek ME, Vij R.

ERJ Open Res. 2017 Aug 17;3(3). pii: 00016-2017. doi: 10.1183/23120541.00016-2017. eCollection 2017 Jul.

46.

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.

Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL.

Lancet Haematol. 2017 Sep;4(9):e431-e442. doi: 10.1016/S2352-3026(17)30140-0. Epub 2017 Aug 17. Erratum in: Lancet Haematol. 2018 Aug;5(8):e332.

47.

Microbial melanins for radioprotection and bioremediation.

Cordero RJB, Vij R, Casadevall A.

Microb Biotechnol. 2017 Sep;10(5):1186-1190. doi: 10.1111/1751-7915.12807. Epub 2017 Aug 14.

48.

Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.

Bhamidipati PK, Fiala MA, Grossman BJ, DiPersio JF, Stockerl-Goldstein K, Gao F, Uy GL, Westervelt P, Schroeder MA, Cashen AF, Abboud CN, Vij R.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2065-2069. doi: 10.1016/j.bbmt.2017.07.023. Epub 2017 Aug 7.

PMID:
28797783
49.

Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study.

Jurczyszyn A, Gozzetti A, Gdula-Argasińska J, Czepiel J, Vij R, Fiala M, Valls DJ, Mądry K, Waszczuk-Gajda A, Grosicki S, Barchnicka A, Crusoe E, Hungria V, Gentile M, Mele G, Ksieniewicz M, Vesole DH, Castillo JJ.

Ann Hematol. 2017 Oct;96(10):1693-1698. doi: 10.1007/s00277-017-3084-9. Epub 2017 Aug 1.

PMID:
28766002
50.

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.

van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R.

Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):555-562. doi: 10.1016/j.clml.2017.06.020. Epub 2017 Jul 4.

PMID:
28735890

Supplemental Content

Support Center